Phase II trial of cisplatin, ifosfamide et mesna in patients with advanced or recurrent malignant mixed mullerian tumors with evaluation of potential molecular targets. - Ramondetta,L.M.; Burke,T.W.; Jhingran,A. (Gynecol Oncol, 2003)